23 Jul, 2026
According to Straits Research, the global asthma therapeutics market size was valued at $25.41 billion in 2025 and is projected to grow from $26.77 billion in 2026 to $41.84 billion by 2034, registering a CAGR of 5.74% during the forecast period 2026–2034.
The global asthma therapeutics market is expanding steadily, primarily fueled by the rising prevalence of asthma worldwide and the increasing number of patients requiring long term disease management. A key driver supporting this growth is the growing burden of respiratory disorders linked to pollution, urbanization, smoking, and lifestyle changes, which resulted in a higher incidence of both pediatric and adult asthma cases. This trend is further intensified by heightened awareness of chronic respiratory disease management and the growing adoption of advanced treatment options such as biologics, combination inhalers, and personalized therapies.
However, the market faces notable restraints, particularly the high cost associated with advanced biologic therapies and inhalation devices. These treatments, while highly effective for severe asthma, often come with notable expense related to manufacturing, cold chain logistics, and ongoing patient monitoring, limiting access in cost sensitive regions. As a result, affordability remains a major barrier to widespread adoption in healthcare systems with limited reimbursement capabilities.
Despite these challenges, the rapid advancement of precision medicine and targeted biologic therapies presents a new scope for market growth. These innovative treatments, designed to address specific inflammatory pathways such as IgE or IL-5, are transforming management approaches for severe and uncontrolled asthma. Additionally, the growing integration of digital inhalers, remote monitoring, and AI-enabled adherence tools is enhancing disease control and enabling more personalized care.
sales@straitsresearch.com